10 Amendments of Françoise GROSSETÊTE related to 2014/2207(INI)
Amendment 11 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
Ca. whereas vaccination is a crucial tool in efforts to combat antibiotic resistance, as it makes it possible to prevent infections from occurring in the first place which would require the use of antibiotics;
Amendment 81 #
Motion for a resolution
Recital Q
Recital Q
Q. whereas it is of paramount importance to encourage pharmaceutical companies to invest in developing new antibiotic compounds, in particular with activity against prevalent multidrug-resistant Gram-negative bacteria such as K. pneumoniae and Acinetobacter, and whereas, to this end, it is necessary to tackle the scientific, regulatory and economic barriers which discourage such investment;
Amendment 100 #
Motion for a resolution
Recital S a (new)
Recital S a (new)
Sa. whereas it is necessary to encourage pharmaceutical laboratories to develop new antibiotics by giving thought to the creation of incentives and alternative economic models to reward innovation;
Amendment 192 #
Motion for a resolution
Paragraph 18
Paragraph 18
18. Regrets that the past 25 years have witnessed both a lack of awareness of the importance of rational use of antimicrobial agents, and antibiotics in particular, and a stagnation in drug development in the field of antimicrobial medicines, due in particular to the emergence of scientific, economic and regulatory barriers;
Amendment 226 #
Motion for a resolution
Paragraph 21 a (new)
Paragraph 21 a (new)
21a. Calls on the Commission and Member States to make use of the ‘adaptive pathways’ programme of the European Medicines Agency and to use all the regulatory tools at their disposal to afford more rapid access to innovative antibacterial treatment for patients;
Amendment 233 #
Motion for a resolution
Paragraph 22 – point a
Paragraph 22 – point a
(a) regulate the prescription of antibiotics for treatment orand prohibit their prescription for purposes of prophylaxis so that an appropriate use of medicines is ensured, specifying the therapeutic objective and selecting the appropriate drug therapy;
Amendment 239 #
Motion for a resolution
Paragraph 22 – point a a (new)
Paragraph 22 – point a a (new)
(aa) encourage the pharmaceutical industry to carry out promotion campaigns for antibiotics only if they are well-considered, and to promote good practices in this regard;
Amendment 269 #
Motion for a resolution
Paragraph 22 – point f a (new)
Paragraph 22 – point f a (new)
(fa) encourage public investment to stimulate research to promote innovative alternative methods of treating bacterial infections;
Amendment 331 #
Motion for a resolution
Paragraph 28 a (new)
Paragraph 28 a (new)
28. Encourages the European Union to promote and take part in any global initiative which makes it possible to improve ways of combating antibiotic resistance and to support research in this field;
Amendment 333 #
Motion for a resolution
Paragraph 28 b (new)
Paragraph 28 b (new)
28b. Calls on the Commission to collaborate in the WHO’s work to develop alternative economic models for antibiotics;